Anti-Human HER-2 (Trastuzumab)

Pricing & Details

Product No.LT1500
Clone
4D5-8
Protein
HER-2/neu
Formats AvailableView All
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
ErbB-2, NEU, NGL, HER2, TKR1, CD340, MLN 19, HER-2/neu
Isotype
Human IgG1κ
Applications
CyTOF®
,
ELISA
,
FC
,
IHC
Prod No.
Size
Price
Avail.
Qty
Add to cart
LT1500-Custom
Custom
In stock
Max:
Min: 1
Step: 1
LT1500-1.0 mg
1.0 mg
$175.00
In stock
Max:
Min: 1
Step: 1
LT1500-5.0 mg
5.0 mg
$650.00
In stock
Max:
Min: 1
Step: 1
LT1500-25 mg
25 mg
$2,450.00
In stock
Max:
Min: 1
Step: 1
LT1500- 50 mg
50 mg
$3,750.00
In stock
Max:
Min: 1
Step: 1
LT1500-100 mg
100 mg
$5,100.00
In stock
Max:
Min: 1
Step: 1

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Human
Expression Host
HEK-293
FC Effector Activity
Active
Immunogen
Human epidermoid carcinoma cells (A431) over-expressing EGFR.
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Trastuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
ELISA
IHC
CyTOF®
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Trastuzumab. Clone 4D5-8 recognizes human erbB-2. This product is for research use only.
Antigen Distribution
Ubiquitous expression with highest expression levels found in the kidney, skin, esophagus, and small intestine.
Background
Trastuzumab is a monoclonal antibody targeting HER2, a 185 kDa transmembrane glycoprotein that contains an extracellular domain and intracellular tyrosine kinase activity. When it is functioning normally, the HER2 pathway supports cell growth and division. On the other hand, the over expression of HER2 propels cell growth beyond its typical range. This overexpression is associated with some cancers, namely breast and stomach, in which the HER2 protein can be expressed up to 100 times more than in typical cells. Trastuzumab induces an immune-mediated response that triggers the internalization and downregulation of HER2 making it an excellent target for immunotherapy. Several clinical studies are under way which show that anti-HER-2/neu antibodies inhibit the growth and proliferation of these tumor cells In vitro as well as In vivo.

Antigen Details

Protein
PubMed
NCBI Gene Bank ID

References & Citations

1. Fendly, B. et al. (1990) Cancer Research 50: 1550-1558.
2. McBride, H. et al. (2019) Pharm Res. 36(12): 177.
3. Zielinski, C. et al. (1997) Int. J. Cancer 73: 875–879
4. Valone, FH. et al. (1995) J. Clin. Oncology 13 (9): 2281-92.
5. Hynes, NE. et al. (1993) Br J Cancer. 68(6): 1140–1145.
Elisa Sandwich Protocol
Flow Cytometry
IHC

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.